The race to produce a coronavirus vaccine accelerated on Monday when the German group BioNTech announced a $135m partnership with Fosun Pharma of China to develop a Covid-19 vaccine, which it said could begin clinical testing in late April.
Fosun will make a $50m equity investment in BioNTech and pay the Mainz-based company a further $85m in vaccine development and commercialisation fees.
The move came as more than 20 companies and public laboratories worldwide are already trying to develop a vaccine against the novel coronavirus as global anxiety about its spread continues to soar.
您已閱讀19%（588字），剩余81%（2527字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。